Updated May 6, 2009 at 11:40 EST.
News agencies confirmed today that Johnson & Johnson ( J&J ) will discuss Priligy approval options with the FDA later this year, the company’s premature ejaculation ( PE ) drug which was approved in seven EU countries earlier this year and is marketed by its European company Janssen Cilag.
J&J received a “not approvable” letter from the FDA back in 2005, but the reason behind the rejection was never disclosed.
Written by the PEhomepage.com Editorial Team.
Back to Articles 
Latest News Archive 
E-mail a Friend
